Biogen (BIIB) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
October 26, 2016 6:59 AM EDTThird quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16%
Nusinersen filed with FDA and EMA for spinal muscular atrophy based on positive interim analysis of ENDEAR trial
Phase 3 Alzheimers disease candidate aducanumab receives FDA Fast Track designation
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including:
Total revenues of $3.0 billion, a 6% increase versus the same quarter in the prior year. Growth was driven by a 10% increase in worldwide TECFIDERA®... More